Biohaven is a pre-revenue biotech with 36.2% analyst upside and breakout momentum, but cash burn, a 2/9 Piotroski score, 15% short interest and 91% implied volatility make it a speculative holding.
Thesis pillars
- Analyst Upside Breakout→Stable
- Cash Burning No Revenue↑Improving
- Widening Quarterly Losses↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Mar 2, 2026
Biohaven Ltd. (BHVN) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $15.24: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality.
Biohaven is a clinical-stage biopharmaceutical company advancing therapeutics in immunology, neuroscience, and oncology, spun off from Biohaven Pharmaceutical Holding Company in October 2022 and trading on the NYSE as "BHVN." Its three prioritized late-stage programs are... Read more
Sell if holding. Engine safety override at $15.24: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Score 5.5/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 116d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Biohaven Ltd.
About Biohaven Ltd.
Biohaven's pipeline is anchored by opakalim (BHV-7000), a Kv7.2/7.3 ion channel activator now in two pivotal Phase 2/3 trials, RISE 2 and RISE 3, evaluating 25-75 mg doses in refractory focal epilepsy with topline results from RISE 3 expected in the second half of 2026. Alongside opakalim, Biohaven is advancing BHV-1300 and BHV-1400, MoDE and TRAP protein degraders headed toward pivotal trials in Graves' disease and IgA nephropathy in 2026, and an early-stage myostatin-activin program targeting obesity.
Biohaven has no commercialized products and no product revenue, funding its pipeline through a Note Purchase Agreement entered in April 2025 with purchasers including Beetlejuice SA LLC, an affiliate of Oberland Capital Management LLC, which provided an initial $250 million tranche of senior secured notes against a 6.25% royalty on future global net sales of troriluzole plus a milestone payment equal to 35% of the funded amount upon FDA or EMA approval of troriluzole or other products. Additional tranches of up to $350 million remain available subject to conditions including FDA approval of troriluzole. Beyond opakalim and the MoDE/TRAP degrader franchise, Biohaven is developing apelin receptor APJ agonists for obesity in collaboration with JiKang Therapeutics, alongside earlier-stage discovery collaborations with Eli Lilly and Novartis.
Show full overview
Biohaven's April 2025 financing terms create a structural mismatch worth noting: the Note Purchase Agreement's royalty and milestone payments are tied specifically to troriluzole, a product not listed among the three key programs (opakalim, the MoDE/TRAP degraders, and the myostatin-activin franchise) that the company prioritized in its fourth-quarter 2025 portfolio and cost-optimization review. If the second and third note tranches remain conditioned on troriluzole's regulatory progress while capital is being directed toward the reprioritized pipeline, funding availability could lag behind the programs the company now says matter most.
See also: Healthcare · Biotechnology
From Biohaven Ltd.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Biohaven Ltd.
Latest news
- NEWS Morgan Stanley Maintains Biohaven at Overweight, Raises Price Target to $21 — fiscal.ai Nov 3, 2026 positive
- NEWS Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $21 — benzinga Nov 3, 2026 positive
- NEWS Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32 — benzinga Oct 31, 2026 positive
- NEWS Deutsche Bank Adjusts Biohaven Price Target to $23 From $26, Maintains Buy Rating — fiscal.ai Oct 30, 2026 negative
- NEWS Biohaven Ltd. Analyst Price Target Adjusted to $25 — fiscal.ai Oct 30, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-05T11:49:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 8.2% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.24: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Prior stop was $14.17. Score 5.5/10, moderate confidence.
Analyst target: $21.36 (+40.2% upside). Prior stop was $14.17. Stop-loss: $14.17.
Quality below floor (2.1 < 4.0).
Biohaven Ltd. trades at a P/E of N/A (forward -8.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
23 analysts rate BHVN, with a consensus score of 4.0/5. 15 analysts publish price targets averaging $24.
What does Biohaven Ltd. do?Biohaven is a clinical-stage biopharmaceutical company advancing therapeutics in immunology, neuroscience, and...
Biohaven is a clinical-stage biopharmaceutical company advancing therapeutics in immunology, neuroscience, and oncology, spun off from Biohaven Pharmaceutical Holding Company in October 2022 and trading on the NYSE as "BHVN." Its three prioritized late-stage programs are opakalim, a Kv7 ion channel activator in Phase 2/3 epilepsy trials; BHV-1300 and BHV-1400, protein degraders for Graves' disease, rheumatoid arthritis, and IgA nephropathy; and a myostatin-activin program for obesity and neuromuscular disease. The company has no commercialized products and partly funds operations through a $25